These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23466485)

  • 1. Early-phase development of cancer prevention agents: challenges and opportunities.
    Perloff M; Steele VE
    Cancer Prev Res (Phila); 2013 May; 6(5):379-83. PubMed ID: 23466485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program: overview, current projects, animal models, agent development strategies, and molecular targets.
    Shoemaker RH; Suen CS; Holmes CA; Fay JR; Steele VE
    Semin Oncol; 2016 Feb; 43(1):189-197. PubMed ID: 26970137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
    Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
    Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid access to preventive intervention development program in the Division of Cancer Prevention of the U.S. National Cancer Institute: an overview.
    Kapetanovic IM
    Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):698-700. PubMed ID: 19240231
    [No Abstract]   [Full Text] [Related]  

  • 5. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.
    Lawrence YR; Vikram B; Dignam JJ; Chakravarti A; Machtay M; Freidlin B; Takebe N; Curran WJ; Bentzen SM; Okunieff P; Coleman CN; Dicker AP
    J Natl Cancer Inst; 2013 Jan; 105(1):11-24. PubMed ID: 23231975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of breast cancer chemopreventive drugs.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Doody LA; Greenwald P
    J Cell Biochem Suppl; 1993; 17G():2-13. PubMed ID: 8007699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of U.S. National Cancer Institute (USNCI) chemoprevention research.
    Johnson KA; Ford LG; Kramer B; Greenwald P
    Acta Oncol; 1994; 33(1):5-11. PubMed ID: 8142125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation-Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic Collaboration.
    Takebe N; Ahmed MM; Vikram B; Bernhard EJ; Zwiebel J; Norman Coleman C; Kunos CA
    Semin Radiat Oncol; 2016 Oct; 26(4):271-80. PubMed ID: 27619249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The chemopreventive agent development research program in the Division of Cancer Prevention of the US National Cancer Institute: an overview.
    Crowell JA
    Eur J Cancer; 2005 Sep; 41(13):1889-910. PubMed ID: 16005206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approaches to the development and marketing approval of drugs that prevent cancer.
    Kelloff GJ; Johnson JR; Crowell JA; Boone CW; DeGeorge JJ; Steele VE; Mehta MU; Temeck JW; Schmidt WJ; Burke G
    Cancer Epidemiol Biomarkers Prev; 1995; 4(1):1-10. PubMed ID: 7894318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming the Early Drug Development Paradigm at the National Cancer Institute: The Formation of NCI's Experimental Therapeutics Clinical Trials Network (ETCTN).
    Massett HA; Mishkin G; Moscow JA; Gravell A; Steketee M; Kruhm M; Han SH; Barry B; Montello M; Zwiebel J; Abrams JS; Doroshow JH; Ivy SP
    Clin Cancer Res; 2019 Dec; 25(23):6925-6931. PubMed ID: 31439585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
    Bando H; Takebe N
    Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention research at the U.S. National Cancer Institute.
    Greenwald P
    Mil Med; 1994 Jul; 159(7):505-12. PubMed ID: 7816223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A National Cancer Clinical Trials Network: recommendations from the Institute of Medicine.
    Nass SJ; Balogh E; Mendelsohn J
    Am J Ther; 2011 Sep; 18(5):382-91. PubMed ID: 21326081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program.
    Minasian LM; Tangen CM; Wickerham DL
    Semin Oncol; 2015 Oct; 42(5):748-63. PubMed ID: 26433556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The preclinical new drug research program of the National Cancer Institute.
    Driscoll JS
    Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.